Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antiemetic/bröstcancer
Länken sparas på Urklipp
Sida 1 från 296 resultat
Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The drug interactions and adverse events that should be considered when individualizing antiemetic therapy for patients undergoing treatment for breast cancer are reviewed.
CONCLUSIONS
A variety of antiemetic agents are available, including antihistamines, dopamine-receptor antagonists,
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A 45-year-old woman who suffered from left breast cancer, 8 cm in diameter, with skin invasion and axillary lymph node involvement but no distant metastasis, underwent neoadjuvant chemotherapy. FEC100 consisting of 5-FU (500 mg/m(2)), epirubicin (100 mg/m(2)) and cyclophosphamide (500 mg/m(2)), were
Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Nausea and vomiting are recognized as two separate and distinct conditions with a wide spectrum of etiologies either directly associated with cancer itself or its treatment. According to the new ranking of chemotherapy side effects, nausea is the number one or the most disturbing side
5-HT3 antiemetic therapy for patients with breast cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Antiemetic treatment should be considered for breast cancer patients receiving moderately emetogenic chemotherapy. Although the extent of chemotherapy-induced emesis is largely dependent on the emetogenic potential of the specific agents employed, patient characteristics such as age and sex also
Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The aim of this study was to investigate if the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines for the prevention of both acute and delayed emesis induced by highly-moderately emetogenic chemotherapy were transferred in daily clinical practice in Italy
Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Retrospective Observational Study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The aim of this study was to identify a high-risk or low-risk population for chemotherapy-induced nausea and vomiting among patients with breast cancer treated with a current standard 3-drug antiemetic regimen and receiving anthracycline.
METHODS
We analyzed data from chemotherapy-naive
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV).
METHODS
Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage
Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
There are little prevalence data in the literature on nonadherence to outpatient antiemetic regimens for prophylaxis of chemotherapy-induced nausea and vomiting (CINV). It is unclear whether adherence with outpatient antiemetic regimens is associated with better CINV control. Our previous
Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Racial minority cancer patients may experience underuse of antiemetic medications to prevent chemotherapy-induced nausea and vomiting (CINV). In addition to its adverse implications for quality of life, antiemetic underuse may contribute to observed disparities in acute illness during chemotherapy.
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients.
METHODS
A total of 134 breast cancer patients receiving
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Chemotherapy consisted of: cyclophosphamide 600, methotrexate 40 and 5-fluorouracil 600
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
To assess the efficacy of adding aprepitant to a 5-HT(3) antagonist and dexamethasone as salvage antiemetic therapy for breast cancer patients receiving their initial cycle of an anthracycline and cyclophosphamide (AC) and failing to achieve complete control of emesis.
METHODS
Eligibility:
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
There has recently been a marked trend to increasing dose intensity in cancer chemotherapy, with or without peripheral blood stem-cell support, which has been associated with a higher frequency of nausea and vomiting. Antiemetic treatment in this setting has not been extensively analysed. From
[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated. Twenty-three patients who were treated with repeated CAF chemotherapy after breast cancer operation received drip-infused granisetron (3 mg/body) to prevent nausea and vomiting.
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
